Patents by Inventor Franco J. Duarte

Franco J. Duarte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10322107
    Abstract: Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: June 18, 2019
    Assignee: Nektar Therapeutics
    Inventors: Franco J. Duarte, Neel K. Anand, Wen Zhang, Pankaj Sharma, Devendrapratap Singh
  • Publication number: 20190175743
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
    Type: Application
    Filed: February 15, 2019
    Publication date: June 13, 2019
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte, Aaron S. Hammons
  • Patent number: 10251959
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: April 9, 2019
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte, Aaron S. Hammons
  • Publication number: 20180362468
    Abstract: Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.
    Type: Application
    Filed: August 22, 2018
    Publication date: December 20, 2018
    Inventors: Franco J. Duarte, Neel K. Anand, Pankaj Sharma, Devendrapratap Singh
  • Patent number: 10081602
    Abstract: Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: September 25, 2018
    Assignee: Nektar Therapeutics
    Inventors: Franco J. Duarte, Neel K. Anand, Pankaj Sharma, Devendrapratap Singh
  • Publication number: 20180016266
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The compounds of Formula I are agonists of the kappa opioid receptor and relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.
    Type: Application
    Filed: September 28, 2017
    Publication date: January 18, 2018
    Inventors: Neel K. Anand, Franco J. Duarte, Wen Zhang, Zhongxu Ren
  • Publication number: 20170368029
    Abstract: Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 28, 2017
    Inventors: Franco J. Duarte, Neel K. Anand, Wen Zhang, Pankaj Sharma, Devendrapratap Singh
  • Publication number: 20170360948
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
    Type: Application
    Filed: August 29, 2017
    Publication date: December 21, 2017
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte, Aaron S. Hammons
  • Patent number: 9815824
    Abstract: Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof. The present disclosure relates to novel compounds and to their use as agonists of the kappa opioid receptor. The disclosure also relates to methods for preparation of the compounds and to pharmaceutical compositions containing such compounds. Kappa opioid agonists that exhibit full agonist properties at the kappa opioid receptor have been widely shown to be efficacious in preclinical models of pain, particularly visceral pain.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: November 14, 2017
    Assignee: Nektar Therapeutics
    Inventors: Neel K. Anand, Franco J. Duarte, Wen Zhang, Zhongxu Ren
  • Patent number: 9782488
    Abstract: The invention provides water-soluble oligomer-beta blocker drug conjugates. A drug conjugate of the invention can be administered by any of a number of administration routes and exhibits properties that are different from the corresponding beta blocker not attached to the water-soluble oligomer.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: October 10, 2017
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte
  • Publication number: 20170253565
    Abstract: Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.
    Type: Application
    Filed: May 24, 2017
    Publication date: September 7, 2017
    Inventors: Franco J. Duarte, Neel K. Anand, Pankaj Sharma, Devendrapratap Singh
  • Patent number: 9688638
    Abstract: Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.
    Type: Grant
    Filed: November 27, 2014
    Date of Patent: June 27, 2017
    Assignee: Nektar Therapeutics
    Inventors: Franco J. Duarte, Neel K. Anand, Pankaj Sharma, Devendrapratap Singh
  • Publication number: 20170022167
    Abstract: Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.
    Type: Application
    Filed: November 27, 2014
    Publication date: January 26, 2017
    Inventors: Franco J. Duarte, Neel K. Anand, Pankaj Sharma, Devendrapratap Singh
  • Publication number: 20160145245
    Abstract: Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds of Formula I described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.
    Type: Application
    Filed: June 27, 2014
    Publication date: May 26, 2016
    Inventors: Neel K. Anand, Franco J. Duarte, Wen Zhang, Zhongxu Ren
  • Patent number: 9233165
    Abstract: The invention relates to (among other things) oligomer-aryloxy-substituted propanamine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated aryloxy-substituted propanamine compounds.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: January 12, 2016
    Assignee: NEKTAR THERAPEUTICS
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte
  • Patent number: 9107956
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: August 18, 2015
    Assignee: NEKTAR THERAPEUTICS
    Inventors: Jennifer Riggs-Sauthier, Lin Cheng, Tacey X. Viegas, Xuyuan Gu, Franco J. Duarte, Wen Zhang
  • Patent number: 9095620
    Abstract: Oligomeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble, non-peptidic oligomer and a pharmaceutically active agent. The oligomeric reagents are useful for, among other things, forming oligomer active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: August 4, 2015
    Assignee: NEKTAR THERAPEUTICS
    Inventor: Franco J. Duarte
  • Publication number: 20140045770
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.
    Type: Application
    Filed: October 16, 2013
    Publication date: February 13, 2014
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Jennifer RIGGS-SAUTHIER, Lin Cheng, Tacey X. Viegas, Xuyuan Gu, Franco J. Duarte, Wen Zhang
  • Patent number: 8598364
    Abstract: The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: December 3, 2013
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Lin Cheng, Tacey X. Viegas, Xuyuan Gu, Franco J. Duarte, Wen Zhang
  • Publication number: 20110269677
    Abstract: The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer.
    Type: Application
    Filed: March 12, 2008
    Publication date: November 3, 2011
    Applicant: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Lin Cheng, Tacey X. Viegas, Xuyuan Gu, Franco J. Duarte, Wen Zhang